Expected to be Significantly Accretive to Teva Non-GAAP EPS, Starting in the Mid-Teens in Year 1 and Approaching 30% by Year 3 JERUSALEM--(BUSINESS WIRE)--Apr. 21, 2015-- Teva Pharmaceutical …
Acquire
In the Mylan case, Bresch actually got paid for something that made business sense — even if it raises serious questions about drug-price regulation. Starting in the ’90s, there’s been a vogue for linking executive pay to the …
The institutional investor owned 354,076 shares of the company’s stock after buying an additional 16,349 shares during the period. United Services Automobile Association owned 0.07% of Mylan worth $13,497,000 at the …
USAA
Eleven states require schools to stock epinephrine, according to Food Allergy Research & Education, an allergy advocacy group that counts Mylan as one of its corporate sponsors. A provision in the Federal Aviation …
Mylan Laboratories Inc.
Mylan executives have been blasted by consumers for hiking the price of the lifesaving EpiPen over 1,000 …
Seek
NEW YORK – Generic drugmaker Mylan is making official its $32 billion-plus offer for over-the-counter medicines maker Perrigo despite opposition from a larger rival that wants to buy Mylan. Continue Reading Below Perrigo …
Mylan Pharmaceuticals — the company behind the price gouging of the EpiPen — is experiencing serious karmic retribution in the stock market. In just five days, Mylan’s stock has tanked by 12.4 percent as outrage …
Panic
First, CEO Bresch may have engaged in insider trading when she sold over 100,000 shares of Mylan stock in advance of the latest price increases. As noted in the second link above, the stock price fell drastically after …
Mylan Laboratories Inc.
Shares of Mylan NV are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment. The …
Valuation
If you are following Valeant Pharmaceuticals (NYSE:VRX)'s psoriasis drug, Brodalumab, you won't want to …